NK1 Antagonists for Pathological Aggression: A Protocol for the Aprepitant for Harmful, Impulsive, and Self-/Aggressive Behavior (AHIMSA-1) Trial

Summary: AHIMSA-1 is a study investigating the benefit of a medication called aprepitant in reducing the frequency and intensity of aggression. Aprepitant is a FDA and Health Canada approved medication that blocks the action of NK1 receptors in the brain. These receptors have been found to mediate aggression. Preliminary results have yielded marked reduction of aggression in participants with Autism Spectrum Disorder, without the usual side-effects seen with anti-psychotics use. According to large clinical trials, aprepitant has no statistically significant side-effects.

Researchers: Jack Sheen, Dr. Jonathan Downar

Who can participate: Participants with ASD (Autism Spectrum Disorder) and frequent outbursts of aggression. Between the ages of 12-65 years.

What’s involved: Four study visits to Toronto Western Hospital, each around 1 to 1.5 hours in length. Study medication dosage is aprepitant 125mg twice a day.

Compensation:$160 upon completion of the study

Interested in participating: If you are interested in participating or have any questions about this study, please email jack.sheen@uhn.ca

Leave a Reply

Close Menu